Biotherapies developed and manufactured in France in compliance with good practices
Clinical studies based on real animal treatments
Easy to use products, delivered solely by veterinarians
Précédent
Suivant
Biotherapies developed and manufactured in France in compliance with good practices
Clinical studies based on real animal treatments
Easy to use products, delivered solely by veterinarians
Précédent
Suivant

08 – Investigation of the immune response to autologous, allogeneic, and xenogeneic mesenchymal stem cells after intra-articular injection in horses.

Pigott JH, Ishihara A, Wellman ML, Russell DS, Bertone AL. Veterinary Immunology and Immunopathology. 2013.

Mesenchymal stem cells have demonstrated immunomodulatory capabilities as well as modest efficacy in animal models of joint injury, warranting further study as a potential treatment of joint disease. The goal of the study was to investigate the blood and synovial immune and histologic response to intra-articular injection of autologous, allogeneic, and xenogeneic bone marrow-derived mesenchymal stem cells (MSC) in horses. The study group consisted of 6 five-year-old Thoroughbred mares that had been injected previously with 15 million, genetically modified autologous, allogeneic, or xenogeneic MSC into the fetlock joints. One group of autologous cells was genetically modified to permit MSC biolocalization in the synovium. To assess response to the injection, synovial biopsies were obtained via arthroscopy 60 days after MSC injection for gross, histologic and molecular analyses. Peripheral blood mononuclear cells were isolated from each horse 120 days after MSC injection and co-cultured with a monolayer of each MSC group to permit quantification of activated CD4+ lymphocytes and cytokine release (ELISA) upon re-exposure to MSC. Arthroscopic examination revealed normal synovium with no grossly detrimental effect to the synovium or cartilage. Intra-articular MSC produced a persistent mononuclear infiltrate for at least 60 days, mostly perivascular, identified as CD3+ lymphocytes. An immune response (significant increase in CD4+ lymphocytes) was detected upon re-exposure to xenogeneic but not to allogeneic or autologous MSC. An inflammatory cytokine release from peripheral blood mononuclear cell/MSC co-cultures was present in all MSC groups but was significantly greater in the xenogeneic group. In conclusion, intra-articular injection of MSC, regardless of cell origin, incited a persistent mononuclear synovitis demonstrating a sustained biologic influence of these cells. Allogeneic cells did not elicit a detectable immune response upon re-exposure using our methods.

For Veterinarians only

For Veterinarians only

Ask your veterinarian for the price of a stem cell injection at his clinic.

Product Pipeline

Range Product Development & optimization Proof of Concept Pilot study Industrialisation /
Manufacturing
Pivotal study Approval Marketing Launch

CANIPREN

VBX-01
Canine osteoarthritis

VBX-01
Canine osteoarthritis

VBX-01
Canine osteoarthritis

CA0102
Atopic dermatitis

CA0103
Atopic dermatitis
Chronic
Inflammatory
Bowel
Disease

Range Product Development & optimization Proof of Concept Pilot study Industrialisation /
Manufacturing
Pivotal study Approval Marketing Launch

FELIPREN

FE0101
Gingivostomatitis

FE0102
Chronic kidney
failure

FE0103
Feline arthrosis

Range Product Development & optimization Proof of Concept Pilot study Industrialisation /
Manufacturing
Pivotal study Approval Marketing Launch

EQUIPREN
OMBISTEM

EQ0101
Equine arthrosis